Evopoint Biosciences

Venture Capital and private equity investors in February rekindled their enthusiasm for late-stage financing rounds to carry Chinese biotechs through a persistent funding crunch. The turnaround seemed

Since the beginning of 2023, it seems that Chinese-originated antibody-drug conjugates (ADCs) have suddenly sprinted from stealth mode into the spotlight on the global biopharma collaboration stage. A

Following two separate deals with Duality Biologics , BioNTech SE has inked another antibody-drug conjugate (ADC) collaboration with another Chinese firm, Suzhou Medilink Therapeutics Ltd. , in a

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Astellas Taps Selecta For Gene The